| 1. |
Reeder CB, Reece DE, Kukreti V, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phaseⅡclinical trial[J]. Leukemia, 2009, 23(7): 1337-1341.
|
| 2. |
Roccaro AM, Hideshima T, Raje N, et al. Bortezomib mediates antiangi ogenesis in multiple myeloma via direct and indirect effects on endothelial cells[J]. Cancer Res, 2006, 66(1): 184-191.
|
| 3. |
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: multiple myeloma (V.2.2011)[EB/OL]. http://www.nccn.org/peofessionals/physician_gle/PDF/myeloma.pdf.
|
| 4. |
Angiolillo AL, Whitlock J, Chen Z, et al. PhaseⅡstudy of gemcitabine in children with relapsed acute lymphoblastic leukemia or acute myelogenous leukemia (ADVL0022): a Children’s Oncology Group Report[J]. Pediatr Blood Cancer, 2006, 46(2): 193-197.
|
| 5. |
Steinherz PG, Seibel NL, Ames MM, et al. PhaseⅠstudy of gemcitabine (difluorodeoxycytidine) in children with relapsed or refractory leukemia (CCG-0955): a report from the Children's Cancer Group[J]. Leuk lymphoma, 2002, 43(10): 1945-1950.
|
| 6. |
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology non-Hodgkin’s lymphoma (V.2.2011)[EB/OL]. http://www.nccn.org/peofessionals/physician_gle/PDF/nhl.pdf.
|
| 7. |
Ahre A, Björkholm M, Mellstedt H, et al. Human leukocyte interferon and intermittent high-dose melphalan-prednisone administration in the treatment of multiple myeloma: a randomized clinical trial from the Myeloma Group of Central Sweden[J]. Cancer Treat Rep, 1984, 68(11): 1331-1338.
|
| 8. |
Nilsson IM, Berntorp E, Lofqvist T, et al. Twenty five years’experience of prophylactic treatment in severe haemophilia A and B[J]. J Intern Med, 1992, 232(1): 25-32.
|
| 9. |
Berntorp E, Boulyjenkow V, Berttler D, et al. Modern treatment of haemophilia[J]. Bull World Health Organ, 1995, 73(5): 691-701.
|
| 10. |
National Hemophilia Foundation. Medical and Scientific Advisory Council (MASAC) recommendations and concerning prophylaxis[M].New York: National Hemophilia Foundation, 1994: 197.
|
| 11. |
Aledort L, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcoraes for severe factor Ⅷ-deftcient haemophiliacs[J]. J Intern Med, 1994, 236(4): 391-394.
|
| 12. |
Sarin S, Mukhtar H, Mirza MA. Prolonged coagulopathy related to superwarfarin overdose[J]. Ann Intern Med, 2005, 142(2): 156.
|
| 13. |
Kristinsson SY. Thrombosis in multiple myeloma[J]. Hematology, 2010, 2010(1): 437-444.
|
1/5
WeChat